---
layout: default
title: Multi-View MRI Approach for Classification of MGMT Methylation in Glioblastoma Patients
---

# Multi-View MRI Approach for Classification of MGMT Methylation in Glioblastoma Patients

**arXiv**: [2512.14232v1](https://arxiv.org/abs/2512.14232) | [PDF](https://arxiv.org/pdf/2512.14232.pdf)

**ä½œè€…**: Rawan Alyahya, Asrar Alruwayqi, Atheer Alqarni, Asma Alkhaldi, Metab Alkubeyyer, Xin Gao, Mona Alshahrani

**åˆ†ç±»**: cs.CV

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºå¤šè§†å›¾MRIæ–¹æ³•ï¼Œåˆ©ç”¨ç©ºé—´å…³ç³»å’Œæ·±åº¦å­¦ä¹ éä¾µå…¥æ€§æ£€æµ‹èƒ¶è´¨æ¯ç»†èƒç˜¤MGMTç”²åŸºåŒ–çŠ¶æ€ã€‚**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **è§†è§‰é‡Œç¨‹è®¡**

<<<<<<< HEAD
**å…³é”®è¯**: `å¤šè§†å›¾MRI` `MGMTç”²åŸºåŒ–æ£€æµ‹` `èƒ¶è´¨æ¯ç»†èƒç˜¤` `å½±åƒåŸºå› ç»„å­¦` `æ·±åº¦å­¦ä¹ ` `éä¾µå…¥æ€§è¯Šæ–­` `ç²¾å‡†åŒ»å­¦` `è‚¿ç˜¤åˆ‡ç‰‡æå–`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šç°æœ‰MGMTç”²åŸºåŒ–æ£€æµ‹ä¾èµ–ä¾µå…¥æ€§æ´»æ£€ï¼Œé£é™©é«˜ä¸”è€—æ—¶ï¼Œç¼ºä¹é«˜æ•ˆéä¾µå…¥æ€§æ–¹æ³•ã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šæå‡ºå¤šè§†å›¾MRIæ–¹æ³•ï¼Œç»“åˆç©ºé—´å…³ç³»å’Œæ·±åº¦å­¦ä¹ ï¼Œé¿å…å¤æ‚3Dæ¨¡å‹ï¼Œæå‡æ£€æµ‹æ•ˆç‡ã€‚
3. å®éªŒæˆ–æ•ˆæœï¼šæ–°æ–¹æ³•åœ¨å¤šä¸ªè¯„ä¼°æŒ‡æ ‡ä¸Šä¼˜äºç°æœ‰æŠ€æœ¯ï¼Œå±•ç¤ºäº†é«˜å‡†ç¡®æ€§å’Œå¯å¤ç°æ€§ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

MGMTå¯åŠ¨å­ç”²åŸºåŒ–çš„å­˜åœ¨æ˜¾è‘—å½±å“èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ˆGBMï¼‰æ‚£è€…åŒ–ç–—æ•ˆæœã€‚ç›®å‰ï¼ŒMGMTå¯åŠ¨å­ç”²åŸºåŒ–çš„ç¡®è®¤ä¾èµ–äºä¾µå…¥æ€§è„‘è‚¿ç˜¤ç»„ç»‡æ´»æ£€ã€‚æœ¬ç ”ç©¶æ¢ç´¢äº†å½±åƒåŸºå› ç»„å­¦æŠ€æœ¯ï¼Œè¿™æ˜¯ä¸€ç§åœ¨ç²¾å‡†åŒ»å­¦ä¸­å…·æœ‰å‰æ™¯çš„æ–¹æ³•ï¼Œæ—¨åœ¨ä»åŒ»å­¦å›¾åƒä¸­è¯†åˆ«é—ä¼ æ ‡è®°ã€‚åˆ©ç”¨MRIæ‰«æå’Œæ·±åº¦å­¦ä¹ æ¨¡å‹ï¼Œæˆ‘ä»¬æå‡ºäº†ä¸€ç§æ–°çš„å¤šè§†å›¾æ–¹æ³•ï¼Œè€ƒè™‘MRIè§†å›¾ä¹‹é—´çš„ç©ºé—´å…³ç³»æ¥æ£€æµ‹MGMTç”²åŸºåŒ–çŠ¶æ€ã€‚é‡è¦çš„æ˜¯ï¼Œæˆ‘ä»¬çš„æ–¹æ³•ä»æ‰€æœ‰ä¸‰ä¸ªè§†å›¾ä¸­æå–ä¿¡æ¯ï¼Œè€Œä¸ä½¿ç”¨å¤æ‚çš„3Dæ·±åº¦å­¦ä¹ æ¨¡å‹ï¼Œé¿å…äº†é«˜å‚æ•°æ•°é‡ã€æ”¶æ•›ç¼“æ…¢å’Œå¤§é‡å†…å­˜éœ€æ±‚ç­‰é—®é¢˜ã€‚æˆ‘ä»¬è¿˜å¼•å…¥äº†ä¸€ç§æ–°çš„è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯ï¼Œå¹¶åŸºäºå¤šä¸ªè¯„ä¼°æŒ‡æ ‡å±•ç¤ºäº†å…¶ä¼˜äºç°æœ‰æ–¹æ³•çš„æ€§èƒ½ã€‚é€šè¿‡å°†æˆ‘ä»¬çš„æ–¹æ³•ä¸æœ€å…ˆè¿›çš„æ¨¡å‹è¿›è¡Œæ¯”è¾ƒï¼Œæˆ‘ä»¬è¯æ˜äº†è¯¥æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬åˆ†äº«äº†å·²å‘è¡¨æ¨¡å‹çš„å¯å¤ç°æµç¨‹ï¼Œé¼“åŠ±é€æ˜åº¦å’Œç¨³å¥è¯Šæ–­å·¥å…·çš„å¼€å‘ã€‚æˆ‘ä»¬çš„ç ”ç©¶çªå‡ºäº†éä¾µå…¥æ€§æ–¹æ³•è¯†åˆ«MGMTå¯åŠ¨å­ç”²åŸºåŒ–çš„æ½œåŠ›ï¼Œå¹¶æœ‰åŠ©äºæ¨è¿›GBMæ²»ç–—ä¸­çš„ç²¾å‡†åŒ»å­¦ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šè®ºæ–‡æ—¨åœ¨è§£å†³èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ˆGBMï¼‰æ‚£è€…MGMTå¯åŠ¨å­ç”²åŸºåŒ–çŠ¶æ€çš„éä¾µå…¥æ€§æ£€æµ‹é—®é¢˜ã€‚ç°æœ‰æ–¹æ³•ä¸»è¦ä¾èµ–ä¾µå…¥æ€§è„‘è‚¿ç˜¤ç»„ç»‡æ´»æ£€ï¼Œè¿™å…·æœ‰é«˜é£é™©ã€é«˜æˆæœ¬å’Œæ—¶é—´å»¶è¿Ÿçš„ç—›ç‚¹ï¼ŒåŒæ—¶ä¼ ç»Ÿå½±åƒåˆ†ææ–¹æ³•ç²¾åº¦æœ‰é™ï¼Œè€Œå¤æ‚3Dæ·±åº¦å­¦ä¹ æ¨¡å‹åˆ™é¢ä¸´é«˜å‚æ•°ã€æ…¢æ”¶æ•›å’Œå¤§å†…å­˜éœ€æ±‚ç­‰æŒ‘æˆ˜ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡çš„æ ¸å¿ƒè§£å†³æ€è·¯æ˜¯è®¾è®¡ä¸€ç§å¤šè§†å›¾MRIæ–¹æ³•ï¼Œé€šè¿‡æ•´åˆMRIæ‰«æä¸­çš„å¤šä¸ªè§†å›¾ï¼ˆå¦‚è½´å‘ã€å† çŠ¶ã€çŸ¢çŠ¶é¢ï¼‰æ¥æ•æ‰ç©ºé—´å…³ç³»ï¼Œä»è€Œæå–æ›´ä¸°å¯Œçš„ç‰¹å¾ç”¨äºMGMTç”²åŸºåŒ–åˆ†ç±»ã€‚è¿™æ ·è®¾è®¡é¿å…äº†ç›´æ¥ä½¿ç”¨3Dæ¨¡å‹ï¼Œå‡å°‘äº†è®¡ç®—å¤æ‚åº¦ï¼ŒåŒæ—¶ä¿æŒäº†ä¿¡æ¯çš„å®Œæ•´æ€§ï¼Œæé«˜äº†æ¨¡å‹çš„æ•ˆç‡å’Œå¯æ‰©å±•æ€§ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šæ•´ä½“æ¶æ„åŒ…æ‹¬æ•°æ®é¢„å¤„ç†ã€è‚¿ç˜¤åˆ‡ç‰‡æå–ã€å¤šè§†å›¾ç‰¹å¾èåˆå’Œåˆ†ç±»æ¨¡å—ã€‚é¦–å…ˆï¼Œä»MRIæ‰«æä¸­æå–è‚¿ç˜¤åŒºåŸŸï¼›ç„¶åï¼Œé‡‡ç”¨æ–°æå‡ºçš„åˆ‡ç‰‡æå–æŠ€æœ¯å¤„ç†å¤šè§†å›¾æ•°æ®ï¼›æ¥ç€ï¼Œé€šè¿‡æ·±åº¦å­¦ä¹ æ¨¡å‹ï¼ˆå¦‚å·ç§¯ç¥ç»ç½‘ç»œï¼‰åˆ†åˆ«å­¦ä¹ æ¯ä¸ªè§†å›¾çš„ç‰¹å¾ï¼›æœ€åï¼Œèåˆè¿™äº›ç‰¹å¾å¹¶è¾“å…¥åˆ†ç±»å™¨ï¼ˆå¦‚å…¨è¿æ¥å±‚ï¼‰é¢„æµ‹MGMTç”²åŸºåŒ–çŠ¶æ€ã€‚æµç¨‹å¼ºè°ƒç«¯åˆ°ç«¯è®­ç»ƒå’Œå¯å¤ç°æ€§ã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ€é‡è¦çš„æŠ€æœ¯åˆ›æ–°ç‚¹æ˜¯å¼•å…¥å¤šè§†å›¾ç©ºé—´å…³ç³»å»ºæ¨¡å’Œæ–°å‹è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯ã€‚ä¸ç°æœ‰æ–¹æ³•çš„æœ¬è´¨åŒºåˆ«åœ¨äºï¼Œå®ƒä¸ä¾èµ–å¤æ‚3Dæ¨¡å‹ï¼Œè€Œæ˜¯é€šè¿‡å¤šè§†å›¾èåˆæ¥æ¨¡æ‹Ÿ3Dä¿¡æ¯ï¼Œä»è€Œåœ¨é™ä½è®¡ç®—èµ„æºéœ€æ±‚çš„åŒæ—¶ï¼Œæé«˜æ£€æµ‹ç²¾åº¦å’Œé²æ£’æ€§ï¼Œè§£å†³äº†ä¼ ç»Ÿæ–¹æ³•åœ¨å†…å­˜å’Œæ”¶æ•›é€Ÿåº¦ä¸Šçš„ç“¶é¢ˆã€‚

**å…³é”®è®¾è®¡**ï¼šå…³é”®è®¾è®¡åŒ…æ‹¬ä½¿ç”¨ç‰¹å®šçš„æ·±åº¦å­¦ä¹ æ¶æ„ï¼ˆå¦‚ResNetæˆ–ç±»ä¼¼ç½‘ç»œï¼‰å¤„ç†æ¯ä¸ªMRIè§†å›¾ï¼Œè®¾è®¡æŸå¤±å‡½æ•°ï¼ˆå¦‚äº¤å‰ç†µæŸå¤±ï¼‰ä¼˜åŒ–åˆ†ç±»ä»»åŠ¡ï¼Œå‚æ•°è®¾ç½®ä¸Šå¯èƒ½æ¶‰åŠæ‰¹é‡å¤§å°ã€å­¦ä¹ ç‡è°ƒæ•´å’Œæ­£åˆ™åŒ–æŠ€æœ¯ã€‚è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯å¯èƒ½åŸºäºå›¾åƒåˆ†å‰²ç®—æ³•ï¼Œç¡®ä¿æå–çš„åˆ‡ç‰‡è¦†ç›–å…³é”®è‚¿ç˜¤åŒºåŸŸï¼Œä»¥æœ€å¤§åŒ–ä¿¡æ¯ä¿ç•™ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

æœ€é‡è¦çš„å®éªŒç»“æœåŒ…æ‹¬ï¼šæ–°æå‡ºçš„å¤šè§†å›¾æ–¹æ³•åœ¨MGMTç”²åŸºåŒ–åˆ†ç±»ä»»åŠ¡ä¸Šï¼ŒåŸºäºå¤šä¸ªè¯„ä¼°æŒ‡æ ‡ï¼ˆå¦‚å‡†ç¡®ç‡ã€å¬å›ç‡ã€F1åˆ†æ•°ï¼‰æ˜¾è‘—ä¼˜äºç°æœ‰æœ€å…ˆè¿›æ¨¡å‹ã€‚å…·ä½“æ€§èƒ½æ•°æ®æœªçŸ¥ï¼Œä½†è®ºæ–‡æŠ¥å‘Šäº†å…¶æ–¹æ³•åœ¨é¿å…å¤æ‚3Dæ¨¡å‹çš„åŒæ—¶ï¼Œå®ç°äº†æ›´é«˜çš„æ£€æµ‹ç²¾åº¦å’Œæ›´å¿«çš„æ”¶æ•›é€Ÿåº¦ã€‚æå‡å¹…åº¦ä½“ç°åœ¨è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯çš„ä¼˜è¶Šæ€§ï¼Œä»¥åŠæ•´ä½“æµç¨‹çš„å¯å¤ç°æ€§ï¼Œä¸ºåç»­ç ”ç©¶æä¾›äº†åŸºå‡†ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶çš„æ½œåœ¨åº”ç”¨é¢†åŸŸä¸»è¦åŒ…æ‹¬ç¥ç»è‚¿ç˜¤å­¦å’Œç²¾å‡†åŒ»å­¦ï¼Œç‰¹åˆ«æ˜¯åœ¨èƒ¶è´¨æ¯ç»†èƒç˜¤çš„è¯Šæ–­å’Œæ²»ç–—è§„åˆ’ä¸­ã€‚å®é™…ä»·å€¼åœ¨äºæä¾›ä¸€ç§éä¾µå…¥æ€§ã€é«˜æ•ˆçš„MGMTç”²åŸºåŒ–æ£€æµ‹æ–¹æ³•ï¼Œå‡å°‘æ‚£è€…æ´»æ£€é£é™©ï¼Œè¾…åŠ©ä¸´åºŠå†³ç­–ï¼Œä¼˜åŒ–åŒ–ç–—æ–¹æ¡ˆã€‚æœªæ¥å½±å“å¯èƒ½æ¨åŠ¨å½±åƒåŸºå› ç»„å­¦åœ¨ç™Œç—‡è¯Šç–—ä¸­çš„æ™®åŠï¼Œä¿ƒè¿›ä¸ªæ€§åŒ–åŒ»ç–—å‘å±•ï¼Œå¹¶ä½œä¸ºåŸºç¡€å·¥å…·ç”¨äºå…¶ä»–è„‘éƒ¨ç–¾ç—…çš„é—ä¼ æ ‡è®°è¯†åˆ«ã€‚
=======
**å…³é”®è¯**: `æ”¾å°„åŸºå› ç»„å­¦` `å¤šè§†å›¾MRI` `æ·±åº¦å­¦ä¹ ` `MGMTç”²åŸºåŒ–æ£€æµ‹` `èƒ¶è´¨æ¯ç»†èƒç˜¤` `éä¾µå…¥æ€§è¯Šæ–­` `ç²¾å‡†åŒ»å­¦` `è‚¿ç˜¤åˆ‡ç‰‡æå–`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šç°æœ‰MGMTç”²åŸºåŒ–æ£€æµ‹ä¾èµ–ä¾µå…¥æ€§æ´»æ£€ï¼Œé£é™©é«˜ä¸”è€—æ—¶ï¼Œè€Œä¼ ç»Ÿ3Dæ·±åº¦å­¦ä¹ æ¨¡å‹å‚æ•°å¤šã€æ”¶æ•›æ…¢ã€å†…å­˜éœ€æ±‚å¤§ã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šæå‡ºå¤šè§†å›¾MRIæ–¹æ³•ï¼Œç»“åˆç©ºé—´å…³ç³»å’Œæ·±åº¦å­¦ä¹ ï¼Œä»ä¸‰ä¸ªè§†å›¾æå–ä¿¡æ¯ï¼Œé¿å…å¤æ‚3Dæ¨¡å‹ï¼Œå¹¶å¼•å…¥æ–°è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯ã€‚
3. å®éªŒæˆ–æ•ˆæœï¼šæ–°æ–¹æ³•åœ¨å¤šä¸ªè¯„ä¼°æŒ‡æ ‡ä¸Šä¼˜äºç°æœ‰æ–¹æ³•ï¼Œå±•ç¤ºäº†éä¾µå…¥æ€§æ£€æµ‹çš„æ½œåŠ›ï¼Œå¹¶æä¾›äº†å¯å¤ç°æµç¨‹ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

MGMTå¯åŠ¨å­ç”²åŸºåŒ–çš„å­˜åœ¨æ˜¾è‘—å½±å“èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ˆGBMï¼‰æ‚£è€…åŒ–ç–—æ•ˆæœã€‚ç›®å‰ï¼Œç¡®è®¤MGMTå¯åŠ¨å­ç”²åŸºåŒ–ä¾èµ–äºä¾µå…¥æ€§è„‘è‚¿ç˜¤ç»„ç»‡æ´»æ£€ã€‚æœ¬ç ”ç©¶æ¢ç´¢äº†æ”¾å°„åŸºå› ç»„å­¦æŠ€æœ¯ï¼Œè¿™æ˜¯ä¸€ç§åœ¨ç²¾å‡†åŒ»å­¦ä¸­å‰æ™¯å¹¿é˜”çš„æ–¹æ³•ï¼Œæ—¨åœ¨ä»åŒ»å­¦å›¾åƒä¸­è¯†åˆ«é—ä¼ æ ‡è®°ã€‚åˆ©ç”¨MRIæ‰«æå’Œæ·±åº¦å­¦ä¹ æ¨¡å‹ï¼Œæˆ‘ä»¬æå‡ºäº†ä¸€ç§æ–°çš„å¤šè§†å›¾æ–¹æ³•ï¼Œè€ƒè™‘MRIè§†å›¾ä¹‹é—´çš„ç©ºé—´å…³ç³»æ¥æ£€æµ‹MGMTç”²åŸºåŒ–çŠ¶æ€ã€‚é‡è¦çš„æ˜¯ï¼Œæˆ‘ä»¬çš„æ–¹æ³•ä»æ‰€æœ‰ä¸‰ä¸ªè§†å›¾ä¸­æå–ä¿¡æ¯ï¼Œè€Œä¸ä½¿ç”¨å¤æ‚çš„3Dæ·±åº¦å­¦ä¹ æ¨¡å‹ï¼Œé¿å…äº†é«˜å‚æ•°æ•°é‡ã€æ”¶æ•›æ…¢å’Œå¤§é‡å†…å­˜éœ€æ±‚ç­‰é—®é¢˜ã€‚æˆ‘ä»¬è¿˜å¼•å…¥äº†ä¸€ç§æ–°çš„è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯ï¼Œå¹¶åŸºäºå¤šä¸ªè¯„ä¼°æŒ‡æ ‡å±•ç¤ºäº†å…¶ä¼˜äºç°æœ‰æ–¹æ³•çš„æ€§èƒ½ã€‚é€šè¿‡å°†æˆ‘ä»¬çš„æ–¹æ³•ä¸æœ€å…ˆè¿›æ¨¡å‹è¿›è¡Œæ¯”è¾ƒï¼Œæˆ‘ä»¬è¯æ˜äº†è¯¥æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬åˆ†äº«äº†å·²å‘è¡¨æ¨¡å‹çš„å¯å¤ç°æµç¨‹ï¼Œé¼“åŠ±é€æ˜åº¦å’Œç¨³å¥è¯Šæ–­å·¥å…·çš„å¼€å‘ã€‚æˆ‘ä»¬çš„ç ”ç©¶çªå‡ºäº†éä¾µå…¥æ€§æ–¹æ³•è¯†åˆ«MGMTå¯åŠ¨å­ç”²åŸºåŒ–çš„æ½œåŠ›ï¼Œå¹¶æœ‰åŠ©äºæ¨è¿›GBMæ²»ç–—ä¸­çš„ç²¾å‡†åŒ»å­¦ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

è®ºæ–‡æå‡ºä¸€ä¸ªå¤šè§†å›¾MRIæ¡†æ¶ï¼Œç”¨äºMGMTç”²åŸºåŒ–åˆ†ç±»ã€‚æ•´ä½“æ¡†æ¶åŸºäºæ·±åº¦å­¦ä¹ æ¨¡å‹ï¼Œä»MRIçš„ä¸‰ä¸ªè§†å›¾ï¼ˆå¦‚è½´å‘ã€å† çŠ¶ã€çŸ¢çŠ¶ï¼‰æå–ç‰¹å¾ï¼Œå¹¶è€ƒè™‘è§†å›¾é—´çš„ç©ºé—´å…³ç³»è¿›è¡Œèåˆï¼Œä»¥å¢å¼ºä¿¡æ¯è¡¨ç¤ºã€‚å…³é”®æŠ€æœ¯åˆ›æ–°ç‚¹åŒ…æ‹¬ï¼šé¿å…ä½¿ç”¨å¤æ‚3Dæ¨¡å‹ï¼Œé€šè¿‡å¤šè§†å›¾æ–¹æ³•å‡å°‘å‚æ•°å’Œå†…å­˜éœ€æ±‚ï¼›å¼•å…¥æ–°çš„è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯ï¼Œæé«˜æ•°æ®é¢„å¤„ç†æ•ˆç‡ã€‚ä¸ç°æœ‰æ–¹æ³•çš„ä¸»è¦åŒºåˆ«åœ¨äºï¼šä¼ ç»Ÿæ–¹æ³•å¸¸ä¾èµ–å•ä¸€è§†å›¾æˆ–å¤æ‚3Dæ¨¡å‹ï¼Œè€Œæœ¬æ–¹æ³•é€šè¿‡å¤šè§†å›¾èåˆå’Œç®€åŒ–æ¶æ„ï¼Œåœ¨ä¿æŒæ€§èƒ½çš„åŒæ—¶é™ä½äº†è®¡ç®—è´Ÿæ‹…ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

å®éªŒç»“æœæ˜¾ç¤ºï¼Œæ–°æ–¹æ³•åœ¨MGMTç”²åŸºåŒ–åˆ†ç±»ä»»åŠ¡ä¸­ï¼ŒåŸºäºå¤šä¸ªè¯„ä¼°æŒ‡æ ‡ï¼ˆå¦‚å‡†ç¡®ç‡ã€çµæ•åº¦ï¼‰ä¼˜äºç°æœ‰æœ€å…ˆè¿›æ¨¡å‹ã€‚è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯çš„å¼•å…¥æ˜¾è‘—æå‡äº†æ€§èƒ½ï¼ŒåŒæ—¶å¤šè§†å›¾æ¡†æ¶é¿å…äº†3Dæ¨¡å‹çš„é«˜è®¡ç®—æˆæœ¬ï¼Œå®ç°äº†é«˜æ•ˆä¸”ç¨³å¥çš„æ£€æµ‹ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶åœ¨ç²¾å‡†åŒ»å­¦é¢†åŸŸæœ‰é‡è¦åº”ç”¨ï¼Œç‰¹åˆ«æ˜¯èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼ˆGBMï¼‰æ²»ç–—ã€‚é€šè¿‡éä¾µå…¥æ€§MRIæ‰«ææ£€æµ‹MGMTç”²åŸºåŒ–çŠ¶æ€ï¼Œå¯è¾…åŠ©ä¸´åºŠå†³ç­–ï¼Œä¼˜åŒ–åŒ–ç–—æ–¹æ¡ˆï¼Œå‡å°‘æ‚£è€…æ´»æ£€é£é™©ã€‚æ­¤å¤–ï¼Œæ–¹æ³•å¯æ¨å¹¿è‡³å…¶ä»–è„‘è‚¿ç˜¤æˆ–ç™Œç—‡çš„é—ä¼ æ ‡è®°æ£€æµ‹ï¼Œæ¨åŠ¨ä¸ªæ€§åŒ–åŒ»ç–—å‘å±•ã€‚
>>>>>>> 1c05e1c356e1f28c2e5e6e14cf6811c0d5120ab7

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> The presence of MGMT promoter methylation significantly affects how well chemotherapy works for patients with Glioblastoma Multiforme (GBM). Currently, confirmation of MGMT promoter methylation relies on invasive brain tumor tissue biopsies. In this study, we explore radiogenomics techniques, a promising approach in precision medicine, to identify genetic markers from medical images. Using MRI scans and deep learning models, we propose a new multi-view approach that considers spatial relationships between MRI views to detect MGMT methylation status. Importantly, our method extracts information from all three views without using a complicated 3D deep learning model, avoiding issues associated with high parameter count, slow convergence, and substantial memory demands. We also introduce a new technique for tumor slice extraction and show its superiority over existing methods based on multiple evaluation metrics. By comparing our approach to state-of-the-art models, we demonstrate the efficacy of our method. Furthermore, we share a reproducible pipeline of published models, encouraging transparency and the development of robust diagnostic tools. Our study highlights the potential of non-invasive methods for identifying MGMT promoter methylation and contributes to advancing precision medicine in GBM treatment.

